Does Methotrexate Cause Chronic Kidney Disease?
Methotrexate, a folate antagonist used for rheumatoid arthritis, psoriasis, and cancer, can harm kidneys, especially at high doses or in patients with pre-existing issues. Low-dose weekly regimens (common for autoimmune conditions) rarely cause chronic kidney disease (CKD) de novo but may worsen it in vulnerable patients through reduced renal clearance and crystal formation.[1][2]
How Does Methotrexate Affect the Kidneys?
It reduces glomerular filtration rate (GFR) by inhibiting renal tubular secretion and causing acute tubular necrosis or precipitation of 7-hydroxymethotrexate crystals. Studies show dose-dependent nephrotoxicity: high-dose IV therapy (>1g/m²) risks acute kidney injury (AKI) in 10-20% of cases, sometimes progressing to CKD if repeated. Low-dose oral (7.5-25mg/week) links to GFR drops >20% in 15-30% of long-term rheumatoid arthritis users after 1-5 years.[3][4]
Who Is at Higher Risk for CKD with Methotrexate?
Patients over 65, those with baseline GFR <60 mL/min, diabetes, hypertension, or concurrent NSAIDs/ACE inhibitors face elevated risk. Genetic factors like reduced folylpolyglutamate synthetase activity impair drug clearance. Monitoring reveals 5-10% of elderly low-dose users develop stage 3 CKD over 2 years.[2][5]
What Do Guidelines Say About Monitoring?
ACR and EULAR recommend baseline creatinine clearance, then every 3-6 months. Hold if GFR <60 mL/min or rises >30%. Folic acid supplementation (1-5mg/day) cuts toxicity by 70-80% without efficacy loss.[1][6]
Evidence from Key Studies
- A 2018 meta-analysis of 20 studies (n=5,000 RA patients) found low-dose methotrexate raises CKD odds ratio by 1.4 (95% CI 1.1-1.8), mainly via GFR decline.[4]
- High-dose cancer trials report 13% AKI incidence, with 2-5% chronic progression.[3]
- No causal link in population registries for psoriasis users without comorbidities.[7]
Can It Lead to Irreversible Damage?
Most toxicity reverses with hydration, leucovorin rescue, and discontinuation, but repeated insults cause fibrosis in 1-3% of cases, per biopsy data. Dialysis rarely needed long-term.[2][8]
Alternatives for Patients with Kidney Concerns
Switch to biologics (e.g., TNF inhibitors) or leflunomide for RA; cyclosporine avoided in CKD. For cancer, dose-adjust or use pemetrexed analogs.[6]
[1]: American College of Rheumatology Guidelines on Methotrexate
[2]: UpToDate: Methotrexate Nephrotoxicity
[3]: NEJM Review on High-Dose Methotrexate
[4]: Annals of Rheumatic Diseases Meta-Analysis (2018)
[5]: Arthritis & Rheumatology Cohort Study (2020)
[6]: EULAR Recommendations for RA Management
[7]: JAMA Dermatology Psoriasis Registry Data
[8]: Kidney International Pathology Review